NOTE: This is ISR’s second installment of our "Biosimilars Primer" series tracking high-level views of US pharmacists. Please also see Biosimilar Primers from US and European physicians and US Payers. Bundling options are available, please contact us at email@example.com for more information.
Biosimilar, Follow-on Biologic (FoB), Follow-on protein product – whatever name you know them by you can’t surf the web, attend a conference, or read an industry publication without running into them.
To say the environment around Biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the Biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues.
This is a "Primer" and is not intended to cover the full range of issues currently at the heart of biosimilar discussions. Rather, we at Industry Standard Research (ISR) took a focused approach to answering a few pointed questions around the views pharmacists have regarding Biosimilars. We took this approach because of the fluid nature of the environment. We took this approach because regardless of the nascent legislation recently enacted in the United States and the relatively low adoption of Biosimilars in Europe; we believe that pharmacists will be a key piece to the Biosimilar puzzle.